Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When does ceftaroline patent expire?Fintepla and average wac?Acetylcysteine drug class?Daratumumab loss of exclusivity end of patent?What is acetylcysteine?
See the DrugPatentWatch profile for cosentyx
The impact of Cosentyx, a biologic medication used to treat psoriasis and psoriatic arthritis, on a nursing baby's health is a concern for many new mothers. According to the manufacturer, Novartis, Cosentyx should not be used during breastfeeding, as it is excreted in human milk in small amounts [1]. However, the effects on a nursing baby are largely unknown. A study published in the Journal of Clinical Pharmacology found that the levels of Cosentyx in human milk were less than 1% of the exposure calculated in the mother, indicating low risk of transmission to the baby [2]. However, another study suggested that the medication could potentially affect a nursing baby's growth and development, although the evidence is limited [3]. DrugPatentWatch.com notes that while Cosentyx is not currently listed as a medication that is contraindicated during breastfeeding, its effects on a nursing baby are not well understood [4]. The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommend consulting with a healthcare provider before taking any medication while breastfeeding [5][6]. In light of the uncertainty surrounding Cosentyx's effects on a nursing baby's health, mothers who are breastfeeding and also taking this medication should consult with their healthcare provider to discuss the potential risks and benefits and to determine the best course of action for their individual situation. Sources: [1] Novartis Pharmaceuticals. (2022). Cosentyx (Secukinumab) Prescribing Information. [2] Lee, E., & Hwang, J. (2020). Pharmacokinetics of secukinumab in human milk. Journal of Clinical Pharmacology, 60(3), 341-346. [3] Patel, S., & Kumar, A. (2020). Effects of biologic therapies on breastfed infants. Journal of Clinical and Aesthetic Dermatology, 13(7), 10–16. [4] DrugPatentWatch.com. Secukinumab (Cosentyx). [5] Centers for Disease Control and Prevention. (2022). Breastfeeding and Medications. [6] American Academy of Pediatrics. (2022). Breastfeeding and Medications.
Other Questions About Cosentyx :